What is a novel avenue in cancer drug discovery?
A novel avenue might involve the combination of different existing drugs in innovative ways to create more effective treatment regimens. For example, combining chemotherapy with immunotherapy or targeted therapies. Additionally, research into nanotechnology for precise drug delivery to cancer cells is also emerging as a promising avenue.
Tell me the full drug discovery story.
The full drug discovery story typically starts with an idea. Maybe a scientist notices a pattern in a disease, like how certain cells behave abnormally. This leads to the search for a molecule that can correct this behavior. During the discovery process, there are many steps of optimization. For instance, if a compound shows some activity against the target but has side effects, chemists will modify its structure to improve its properties. In addition to lab - based research, data from patient records and epidemiology can also play a role. Once a potential drug candidate is identified, it goes through rigorous testing, not just for its effectiveness in treating the disease but also for its long - term safety and how it interacts with other drugs patients might be taking.
Is there a targeted drug for the spread of cervical cancer?
Yes. For example, anti-VegG drugs (such as bevacizhu), VegG is a pro-inflammatory factor that can promote the growth and spread of olive cancer cells, bevacizhu can block the binding of VegG to its receptor, and suppress the growth and migration of olive cancer cells;Parp inhibition drugs (such as olaparib) can prevent olive cancer cells from undergoing the correct DNA repair process, causing serious genetic mutations in cancer cells and death; ATR inhibition drugs (such as VE - 822). ATR is an important molecular response to DNA damage in cells. It will be activated after DNA double-strand breaks. VE - 822 can selectively inhibit ATR and promote the death of malignant tumor cells. Anti-HEL2 drugs (such as tocilbizumb). HEL2 is a targeted protein that is highly expressed in some patients with malignant tumors. Tocilbizumb can bind to HEL2 and suppress the growth and spread of malignant tumors. These targeted drugs could be combined with traditional surgery or chemotherapy to improve the treatment effect of the spread of the cancer. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
What are the key stages in the full drug discovery story?
The key stages include target identification, where scientists figure out what biological entity is involved in the disease. Then there's lead compound discovery, which is finding substances that might interact with the target. Next is pre - clinical testing on animals to check safety and efficacy. And finally, clinical trials in humans with different phases to ensure the drug is safe and effective for people.
What are some recent drug discovery success stories?
The discovery of new drugs for Hepatitis C is also a big deal. Scientists were able to develop drugs that directly target the virus and can cure Hepatitis C in a matter of weeks in most cases. This was a huge step forward compared to the previous treatments which had many side effects and were less effective.
Salivary cancer effective drug research and development
The research and development of drugs for Salivary Gland Cancer had made progress in many aspects. In terms of drug therapy research based on the ESCat classification, the drug therapy for Salivary Gland Cancer was divided into four types: one was the NTrK fusion inhibition drugs Entritini and Larotinib, and the other was targeted at the over-expression of HEL2.(For example, trastuzumab-pertuzumab-pertuzumpertuzum-pertuzum-pertuzumpertuzum In terms of anti-HEL2 therapy, studies have shown that trastulizumab-plus-taxotere in the treatment of HEL-amplified saliva gland cancer has achieved an objective response rate (ORR) of 70.2%, and in the treatment of patients with HEL2 overexpressed or amplified saliva gland cancer with patotubizumab-plus-tratotubizumab-plus-taxotere, the ORR has reached 60%. In 2021, a study conducted by AscO used the ADC drug, DS - 8201, to treat patients with SADC as second-line therapy. The PR rate reached 47.1% and the DOR was 12.9 months. It was confirmed that HER-2 was a driver gene of saliva gland cancer. In a study reported at the 2024 Annual Meeting of the American Society of Clinic Oncers (Asco), pirotinib (an oral irreversible pan-Her receptor Tyrosin Kinase) was used to treat HER2 variant advanced stage Salivary Gland Cancer (SGC). The efficacy and safety of pirotinib in patients with HER2 amplification, over-expression, or mutation in advanced SGC were being evaluated. In terms of anti-androgen therapy, anti-androgen therapy for Salivary Ductal Carcinomas (SDCs) was the highest AR expression subclass in saliva glands. The study showed that leuprorelin + bicalutamide treatment for patients with Salivary Ductal Carcinomas (34 SDCs and 2 other patients) achieved a PR + PR rate of 41.7%. After 24 patients (19 SDCs) failed previous ADT, they were treated with abraterone + Prednisone + LHGH Analogy as a salvage plan. The ORR was 21% and the DPR was 62.5%. In addition, in the case of a malignant tumor of the saliva gland, the study found that the small molecular inhibition of MMD2 could reduce the number of cancer stem cells and reduce the relapse rate of mice. Although there was no FDa-approved drug for the treatment of this cancer, it provided a new direction for the treatment of saliva gland cancer. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is the targeted drug for liver cancer metastasizing useful?
If liver cancer patients had metastasized, they could use targeted drugs, but they had to pay attention to their own condition. For patients with liver cancer lung metastasizing, they could take targeted drugs such as sorafenib, gefitini, or afatini. Sorafenib was more commonly used to treat untreatable or distant cancerous tumors. However, if there was severe liver function decline, large amounts of ascitic fluid, digestive tract bleeding, hepatic epilepsy, repeated infection, and other conditions, it was not suitable to use targeted drugs. At the same time, although targeted drugs had a certain effect on many liver cancer patients, some patients had no effect at all, and the cost was relatively high. Therefore, it was necessary to choose according to the individual's actual situation. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is there reimbursement for Changde lung cancer targeted drug?
Based on the information provided so far, it was impossible to determine whether Changde's targeted lung cancer drug was eligible for reimbursement. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is there an imitation of the targeted drug for cervical cancer in India?
Yes, there was an Indian imitation version of the targeted drug. For example, there was an Indian version of Niraparini, but its price was difficult for ordinary family patients to afford. A box of Indian version of Niraparini cost about 20000 yuan. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is there a targeted drug in the ribs of cardiac cancer metastasizing?
Cardia cancer with rib metastasizing was stage IV. For this case, Folfox protocol chemotherapy + anti-neoplastic drugs such as bevacizumi or cetuxed targeted therapy could be used. In addition, targeted drugs for the treatment of cardiac cancer also included erlotinib, gefitinib, nimotuzumab, pembrolizub, and so on. However, different targeted drugs had their own applications. For example, erlotinib was suitable for the treatment of patients with locally advanced, relapsed, or metastasized non-small cell lung cancer with mutations in the egF-receptor protein protein gene; Gefitini was used for the treatment of patients with locally advanced or metastasized non-small cell lung cancer who had failed at least one prior chemotherapy; Cetuxed was suitable for patients with wild-type RAS gene in the Coloreceptor Cancer; Nimotubiza is indicated for the auxiliary treatment of patients with stage III non-small cell lung cancer with positive expression of the Epidermal Growth factor receptor; pembrolizub is indicated for adult patients with positive expression of PD-L1 or anplastic large cell leukemia who have progressed during or after first-line systematic chemotherapy. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is there any reaction to the infusion of the anti-cancer drug for esophagus cancer? Can it be cured?
Patients with esophagus cancer may have the following reactions after receiving anti-cancer drugs: 1. ** Intestinal reactions **: The symptoms are nausea, vomiting, loss of appetite, etc. Some patients may also have constipation, diarrhea, etc. 2. ** Hair loss **: Due to the certain toxicity of chemicals, some drugs may cause a large amount of hair loss, but this hair loss symptom is irreversible after stopping chemotherapy. 3. Bone marrow suppression: Anti-cancer drugs can damage normal cells while killing cancer cells, resulting in bone marrow suppression such as white blood cells and blood clot reduction. Whether or not esophagus cancer could be cured depended on many factors, such as the stage of the cancer, the patient's physical condition, and the effectiveness of the treatment. Early stage esophagus cancer could be cured through aggressive treatment (such as surgery, chemotherapy, etc.), while for patients with advanced esophagus cancer, it was relatively difficult to completely cure them, but reasonable treatment could control the progression of the disease, relieve symptoms, and prolong survival. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>